Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.



Company Overview and News

2
Mallinckrodt (MNK) Beats on Q2 Earnings and Sales, Ups View

2018-08-08 zacks
Shares of Mallinckrodt Public Limited Company (MNK - Free Report) are up 20.9% after the company reported strong results for the second quarter of 2018 and upped its annual guidance. Performance of hospital products especially Inomax and Ofirmev were impressive.
SGEN VRTX OAS BAX SCMP

4
UroGen Pharma Appoints Peter P. Pfreundschuh as Chief Financial Officer

2018-08-08 globenewswire
Life Sciences Veteran Brings Extensive Global Finance, Commercial Operations and Business Development Experience to Prepare UroGen for its Transition from a Clinical Stage Company to Commercialization
IMMU URGN SCMP

15
EyeGate Pharmaceuticals Announces New Board Member, Peter Greenleaf

2018-08-07 globenewswire
WALTHAM, Mass., Aug. 07, 2018 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced the appointment of Peter Greenleaf to its Board of Directors. Mr. Greenleaf was elected to the Board at the Company’s annual stockholders meeting on July 10, 2018.
EYEG CERC CERCZ EYEGW SCMP BDSI CERCW

0
Cerecor Announces Expansion of Leadership Team

2018-07-16 globenewswire
BALTIMORE, July 16, 2018 (GLOBE NEWSWIRE) -- Cerecor Inc. (NASDAQ:CERC), today announced executive management changes that continue the Company’s strategic shift and further align its organizational structure to its long-term strategy. Specifically, effective today, the Company announced the appointment of Joe Miller as Chief Financial Officer, Dr. Pericles Calias as Chief Scientific Officer and Jamie Harrell as Executive Vice President of Marketing and Investor Relations.
CERC CERCZ SCMP CERCW

200
Mallinckrodt: The Cheapest Stock In Global Healthcare

2018-06-08 seekingalpha
Contrary to shorts, Mallinckrodt is nowhere near bankruptcy and has nearly 4 years ahead without significant obligations.
VRX IPXL VRX MNK SCMP ENDP AMRX

50
BioDelivery Sciences Announces Closing of $50 Million Equity Financing and Appointment of Peter Greenleaf as Chairman of the Board

2018-05-22 globenewswire
RALEIGH, N.C., May 22, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced it has closed its previously announced $50 million registered direct offering of newly designated Series B Non-Voting Convertible Preferred Stock. The offering closed on May 21, 2018, yielding net proceeds of $48.9 million to BDSI.
CERC SCMP BDSI

1240
Tracking John Paulson's Paulson & Co. Portfolio - Q1 2018 Update

2018-05-18 seekingalpha
This article is part of a series that provides an ongoing analysis of the changes made to John Paulson's 13F stock portfolio on a quarterly basis. It is based on Paulson's regulatory 13F Form filed on 05/15/2018. Please visit our Tracking John Paulson's Paulson & Co. Portfolio series to get an idea of his investment philosophy and our previous update for the fund's moves during Q4 2017.
SNI BGX DISCB VST DISCA TSU TWX AU DISCK ENL BGLF STAY SHPG VIAB HAWK AABA DST OSG.WI SSNC AEM INSW AGG SYMX AET DISC FOX TMUSP TMUS RGORF VRX BKD UTX GOLD BX 2840 TWC OGISD NSW OGSRW MDT BGB SGYP SES CZR OGSWW OGISZ XLGLF SCMP QCOM INSW.WI FOXA OGSBW ENDP NMRK NXPI XL CTL RRS GLD AULGF OSG VRX MYL AGN ODP EGN MON SGYPW HZNP OSGB DISH OVSPW CACQ COL GOLD OVSPA OAS T OVSPD VSTE MNK THM

10
Harte Hanks to Appoint Four New Independent Directors to the Board

2018-05-17 globenewswire
SAN ANTONIO, May 17, 2018 (GLOBE NEWSWIRE) -- Harte Hanks (NYSE:HHS) today announced that it will appoint Timothy “Bant” Breen, Maureen O’Connell and Martin Reidy to its Board of Directors, effective June 15, 2018. Harte Hanks has accepted the resignations of current directors Christopher Harte, Scott Key and Judy Odom, also effective June 15, 2018. William F. Farley has also announced his resignation, to be effective upon appointment of a replacement.
HHS SCHL SCMP

14
BioDelivery Sciences Announces Agreement with Broadfin Capital on Comprehensive Plan to Strengthen Business

2018-05-17 globenewswire
RALEIGH, N.C., May 17, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ:BDSI) today announced that it has entered into an agreement with an affiliate of Broadfin Capital LLC (Broadfin), a large BDSI stockholder, to reconstitute BDSI’s Board of Directors and to significantly strengthen BDSI’s financial position. The closing of this agreement is subject to and effective upon the closing of BDSI’s $50 million equity financing announced earlier today.
MNK SCMP BDSI

314
Synergy Pharmaceuticals 'Evaluating All Options': Does That Mean A Formal Strategic Review?

2018-05-16 seekingalpha
2018 Q 1 Sales of Trulance missed analyst expectations, while Allergan reported an 8% increase in Linzess for the previous quarter.
IRWD SGYP AGN SGYPW SCMP

92
Hospital Product Sales Drive Mallinckrodt (MNK) Q1 Earnings

2018-05-10 zacks
Following the release of first-quarter 2018 results, shares of Mallinckrodt Public Limited Co. (MNK - Free Report) moved up 7.3%.
EXEL MDCO BAX SCMP

4
FDA Finds Mallinckrodt's Supplemental NDA For Amitiza Lacking

2018-05-04 seekingalpha
April was supposed to be a big month for Mallinckrodt (MNK) and newly acquired Sucampo Pharmaceuticals. Sucampo's main drug, Amitiza (lubiprostone), treats chronic idiopathic constipation (CIC) in adults, irritable bowel syndrome with constipation (IBS-C) in adult women and opioid-induced constipation (OIC) in adults suffering from chronic non-cancer related pain. Sucampo was seeking approval for its leading drug Amitiza to treat children 6 to 17 years of age for pediatric functional constipation ("PFC").
SCMP

9
Lysogene Strengthens Board of Directors with Appointment of Dr. Peter Lichtlen

2018-04-23 globenewswire
CAMBRIDGE, Mass. and PARIS, April 23, 2018 (GLOBE NEWSWIRE) -- Lysogene (FR0013233475 – LYS), a leading biopharmaceutical company pioneering gene therapy technologies to treat central nervous system (CNS) diseases, appointed Dr. Peter Lichtlen to the Board of Directors, as a non-executive, independent member effective from April 1, 2018. Dr. Peter Lichtlen was Chief Medical Officer at Sucampo Pharmaceuticals Inc.
SCMP RGNX

78
Novartis and Other Drug Stocks With FDA Catalysts in April

2018-04-10 zacks
Last year turned out to be pretty good for pharma and biotech stocks as far as FDA decisions are concerned. The regulatory body approved 46 novel drugs, easily surpassing 2016’s total tally of 22.
VRTX GILD UNP PCRX NVS RARE SCMP PFSCF GWP CLVS

79
CRISPR Therapeutics Announces the Appointment of Steve Caffé as Head of Regulatory Affairs

2018-04-04 globenewswire
ZUG, Switzerland and CAMBRIDGE, MA., April 04, 2018 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (NASDAQ:CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, announced the appointment of Steve Caffé, M.D., as Head of Regulatory Affairs. Dr. Caffé brings to CRISPR a 25-year track record in global product development and regulatory affairs, having held senior leadership positions at many leading biotechnology and pharmaceuticals companies.
VRTX AMAG CRSP RARX BAX SCMP

Related Articles

BLDP: Ballard Power Systems Analysis and Research Report

2018-08-13 - Asif

Core Business At Ballard, Ballard Power Systems is building a clean energy growth company. Ballard Power Systems is recognized as a world leader in proton exchange membrane (“PEM”) fuel cell power system development and commercialization. The company's principal business is the design, development, manufacture, sale and service of PEM fuel cell products for a variety of applications, focusing on its power product markets of Heavy-Duty Motive (consisting of bus, truck, rail and marine applications), Portable Power, Material Handling and Backup Power, as well as the delivery of Technology Solutions, including engineering services, technology transfer, and the license and sale of its extensive intellectual property portfolio and fundamental knowledge for a variety of fuel cell applications. A fuel cell is an environmentally clean electrochemical device that combines hydrogen fuel with oxygen (from the air) to produce electricity. The hydrogen fuel can be obtained from natural g...

MARA: Marathon Patent Group Analysis and Research Report

2018-08-13 - Asif

Overview Marathon Patent Group was incorporated in the State of Nevada on February 23, 2010 under the name Verve Ventures, Inc. On December 7, 2011, the company changed its name to American Strategic Minerals Corporation and were engaged in exploration and potential development of uranium and vanadium minerals business. In June 2012, the company discontinued its minerals business and began to invest in real estate properties in Southern California. In October 2012, the company discontinued its real estate business when its former CEO joined the firm and the company commenced its IP licensing operations, at which time the Company’s name was changed to Marathon Patent Group, Inc. On November 1, 2017, the company entered into a merger agreement with Global Bit Ventures, Inc. (“GBV”), which is focused on mining digital assets. Marathon Patent Group has since purchased its cryptocurrency mining machines and established a data center in Canada to mine digital assets. Following the me...

ECYT: Endocyte Analysis and Research Report

2018-08-13 - Asif

Business and Organization Endocyte, Inc. is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer. The Company uses drug conjugation technology to create novel therapeutics and companion imaging agents for personalized targeted therapies. The agents actively target receptors that are over-expressed on diseased cells relative to healthy cells, such as prostate specific membrane antigen (“PSMA”) in prostate cancer. This targeted approach is designed to safely enable the delivery of highly potent drug payloads. The companion imaging agents are designed to identify patients whose disease over-expresses the target of the therapy and who are therefore more likely to benefit from treatment. In September 2017, the Company entered into a Development and License Agreement (the “License Agreement”) with ABX advanced biochemical compounds – Biomedizinische Forschungsreagenzien GmbH (“ABX”), pursuant to which the Company acquired exclusive ...

CUSIP: 864909106